Lab Med Online.  2022 Oct;12(4):227-234. 10.47429/lmo.2022.12.4.227.

Recommendations for the Verification of Quantitative Molecular Hemato-Oncology Tests

• Kim JJ
• Park S
• Cho Y
• Ha J
• Shin S
• Lee ST

• KMID: 2538610
• DOI: http://doi.org/10.47429/lmo.2022.12.4.227

Abstract

Quantitative molecular genetic tests are increasingly used for the detection and quantification of target molecules or genetic alterations. When introducing a new assay into clinical laboratories, it is necessary to verify the manufacturers’ claimed performance characteristics within individual laboratories. Appropriate assay verification procedures are essential to ensure the quality of test results in clinical laboratories. This study aimed to provide recommendations for the verification of quantitative molecular genetic testing focused on the hemato-oncology field in clinical genetic laboratories. Based on a literature review, we provide recommendations for the performance verification of quantitative molecular hemato-oncology tests. The performance characteristic elements that comprise the verification procedures are presented and exemplified. These recommendations can assist individual clinical laboratories in verifying quantitative molecular diagnostic assays.

Keyword

Verification; Quantitative PCR; Digital PCR; Real-time PCR; Molecular diagnostic techniques

Reference

1. Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021; 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 138:2753–67. DOI: 10.1182/blood.2021013626. PMID: 34724563. PMCID: PMC8718623.

2. Mazaika E, Homsy J. 2014; Digital droplet PCR: CNV analysis and other applications. Curr Protoc Hum Genet. 82:7. 24.1-13. DOI: 10.1002/0471142905.hg0724s82. PMID: 25042719. PMCID: PMC4355013.

3. Halling KC, Schrijver I, Persons DL. 2012; Test verification and validation for molecular diagnostic assays. Arch Pathol Lab Med. 136:11–3. DOI: 10.5858/arpa.2011-0212-ED. PMID: 22208481.

4. Clinical, Laboratory Standards Institute. 2012. Evaluation of detection capability for clinical laboratory measurement procedures; Approved guideline-Second edition. CLSI document EP17-A2. Clinical and Laboratory Standards Institute;Wayne, PA:

5. Association for Molecular Pathology. Molecular Diagnostic Assay Validation : Update to the 2009 AMP Molecular Diagnostic Assay Validation White Paper. https://www.amp.org/AMP/assets/File/resources/201503032014AssayValidationWhitePaper.pdf. Updated on Sep 2014.

6. Clinical, Laboratory Standards Institute. 2012. Molecular methods for clinical genetics and oncology testing; Approved guideline-Third edition. CLSI document MM01-A3. Clinical and Laboratory Standards Institute;Wayne, PA:

7. Clinical, Laboratory Standards Institute. 2012. Quality management for molecular genetic testing; Approved guideline. CLSI document MM20-A. Clinical and Laboratory Standards Institute;Wayne, PA:

8. Clinical, Laboratory Standards Institute. 2020. Evaluation of linearity of quantitative measurement procedures, 2nd Edition. CLSI guideline EP06-Ed2. Clinical and Laboratory Standards Institute;Wayne, PA:

9. Clinical, Laboratory Standards Institute. 2014. User verification of precision and estimation of bias; Approved guideline-Third edition. CLSI document EP15-A3. Clinical and Laboratory Standards Institute;Wayne, PA:

10. Clinical, Laboratory Standards Institute. 2010. Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline-3rd edition. CLSI guideline EP28-A3c. Clinical and Laboratory Standards Institute;Wayne, PA:

11. Standard: Establishment and verification of performance specifications. 42 CFR § 493.1253, Oct. 1, 2015. https://www.govinfo.gov/content/pkg/CFR-2015-title42-vol5/pdf/CFR-2015-title42-vol5-sec493-1253.pdf.

12. College of American Pathologists. Molecular pathology checklist. North-field, IL: College of American Pathologists;2021.

13. Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A, Dequeker E, et al. 2010; A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet. 18:1276–88. DOI: 10.1038/ejhg.2010.101. PMID: 20664632. PMCID: PMC3002854.

14. Jennings L, Van Deerlin VM, Gulley ML. 2009; Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 133:743–55. DOI: 10.5858/133.5.743. PMID: 19415949.

15. Chung HJ, Hur M, Yoon S, Hwang K, Lim HS, Kim H, et al. 2020; Performance evaluation of the QXDx BCR-ABL %IS droplet digital PCR assay. Ann Lab Med. 40:72–5. DOI: 10.3343/alm.2020.40.1.72. PMID: 31432643. PMCID: PMC6713652.

16. Broeders S, Huber I, Grohmann L, Berben G, Taverniers I, Mazzara M, et al. 2014; Guidelines for validation of qualitative real-time PCR methods. Trends Food Sci Technol. 37:115–26. DOI: 10.1016/j.tifs.2014.03.008.

17. Jennings LJ, Smith FA, Halling KC, Persons DL, Kamel-Reid S. 2012; Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. Arch Pathol Lab Med. 136:33–40. DOI: 10.5858/arpa.2011-0136-OA. PMID: 22208485.

18. Armbruster DA, Pry T. 2008; Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 29(Suppl 1):S49–52.

19. Shrivastava A, Gupta VB. 2011; Methods for the determination of limit of detection and limit of quantitation of the analytical methods. Chron Young Sci. 2:21–5. DOI: 10.4103/2229-5186.79345.

20. BIO-RAD. Rare Mutation Detection Best Practices Guidelines. https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6628.pdf. Last accessed on Aug 2022.

21. Yuan D, Cui M, Yu S, Wang H, Jing R. 2019; Droplet digital PCR for quantification of PML-RARα in acute promyelocytic leukemia: a comprehensive comparison with real-time PCR. Anal Bioanal Chem. 411:895–903. DOI: 10.1007/s00216-018-1508-6. PMID: 30617397.

22. Wolstencroft EC, Hanlon K, Harries LW, Standen GR, Sternberg A, Ellard S. 2007; Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation. J Mol Diagn. 9:42–6. DOI: 10.2353/jmoldx.2007.060083. PMID: 17251334. PMCID: PMC1867420.

23. Schnittger S, Bacher U, Haferlach T, Wendland N, Ulke M, Dicker F, et al. 2012; Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood. 119:3151–4. DOI: 10.1182/blood-2011-10-383323. PMID: 22331186.